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INTRODUCTION
Combined fi rst trimester screening (cFTS) based on serum and 
ultrasonography markers is offered to women to identify those 
who are at increased risk of carrying a baby affected with Down 
syndrome (DS).(1) cFTS has a detection rate of 84%–90%(2-4) and 
a false-positive rate of 5%. Women found to have an increased 
risk of aneuploidy have traditionally been offered invasive 
prenatal diagnosis (IPD) to confi rm the result. Although IPD 
provides an extremely accurate diagnosis, there is a procedure-
related risk of miscarriage of up to 1%.(5) Noninvasive prenatal 
testing (NIPT) for DS using cell-free DNA (cfDNA) from maternal 
blood was developed in 2008(6,7) and became commercially 
available three years later.(8) There are now numerous companies 
providing NIPT for the most common aneuploidies(9) and selected 
microdeletions.(10,11) NIPT for DS is a highly accurate screening 
test with a sensitivity of 99.2% and a specifi city of 99.1%,(12) and 
it can be performed from ten weeks of gestation. There is still a 
small risk of a false-positive result, primarily due to the fact that 
the cell-free fetal DNA component of cfDNA is derived from the 
placenta(13) and confi ned placental mosaicism may be a source 
of additional chromosome 21 sequences. Consequently, it is 
essential to remember that NIPT is only a screening method 
and a subsequent invasive test is recommended to confi rm a 
positive result.
Some countries are beginning to implement the technology 
into their national health programmes,(14,15) and recent research 
highlights differences in how NIPT is being implemented 
throughout the world.(16) Unlike many countries, Singapore does 
not have a free healthcare system; all patients have to contribute 
to the costs of their care, either as private or subsidised patients. 
cFTS is offered to all women in Singapore as part of their routine 
care, at a cost of approximately SGD 130 for subsidised patients 
and SGD 270 for private patients. NIPT was introduced to 
Singapore in 2013 and is becoming more widely used, although 
it is currently available only to private patients. The costs for NIPT 
tests range from SGD 1,100 to SGD 2,500, making it far more 
expensive than cFTS.
When implementing a new service into clinical practice, 
stakeholders’ opinions and preferences must be taken into 
consideration to ensure that the needs of both the service users 
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and providers are met. Effective informed consent would require 
a combination of input from the prospective parents and health 
professionals (HPs), in order for effective patient counselling 
programmes and educational materials to be developed. In 
addition, it is important that cultural and social factors are taken 
into consideration when advising women of their options for 
prenatal testing.(17,18) For example, a study carried out in Europe 
and Asia demonstrated that women from Northern Europe 
believed that choices for prenatal testing should refl ect parental 
choice. However, in Southern Europe, China and India, the 
majority of women felt that all women should have a prenatal 
test.(19) Consequently, it is important that culturally specifi c data 
is gathered to inform the ongoing implementation of NIPT in 
Singapore.
One method for evaluating preferences is the discrete 
choice experiment (DCE). DCEs are based on the premise that 
any service or product can be evaluated by different levels of 
its characteristics, described as attributes.(20) Individuals are 
presented with a series of scenarios, each containing two or 
more choices involving the attributes of interest, presented at 
different levels. For each scenario, they are asked to choose their 
preferred option. The responses are modelled statistically, and the 
importance of each attribute to an individual’s decision-making 
and willingness to make a trade-off between attributes is then 
assessed. DCEs are an essential aid to predict test uptake and 
can be used to guide policy implementation. Previous research 
using DCEs to examine preferences for prenatal tests, including 
NIPT, has shown that the main concern of women is the safety 
of their baby, whereas the primary consideration for HPs is the 
accuracy of the test.(21,22) A DCE comparing the preferences 
of women and HPs from nine different countries, including 
Singapore, has recently been published.(23) Herein, we report 
detailed fi ndings of the preferences of women and HPs for 
NIPT from the Singapore cohort, with the aim of gaining an 
understanding of the challenges women and HPs may face upon 
widespread implementation of the test in Singapore. Preferences 
for four prenatal test attributes – accuracy, time of results, risk of 
miscarriage and amount of information provided – were assessed.
METHODS
The study design and analysis followed current guidelines for 
conducting DCEs.(24,25) The study was approved by the National 
Healthcare Group Domain Specifi c Review Board, Singapore 
(DSRB no. D/00803).
We recruited a convenience sample of pregnant women 
attending two maternity clinics for routine clinical care at 
National University Hospital (NUH), Singapore. The women 
were approached to participate in the study while waiting for 
their clinical appointment. Those who agreed to participate were 
given an information sheet describing DS, and the tests for DS 
screening and diagnosis. A researcher was available to discuss 
any questions regarding the questionnaire and study. Using 
convenience sampling, we also recruited HPs who were providing 
antenatal care and counselling for DS screening and diagnostic 
testing from NUH and Singapore General Hospital. The recruited 
HPs from the two centres were requested to complete Section 
A (i.e. DCE choice sets) and Section B of the questionnaire, as 
well as some demographic questions. Questionnaires were also 
handed out to Singaporean HPs at the Singapore International 
Congress of Obstetrics and Gynaecology 2013 meeting. Suitable 
participants were approached in person and requested to either 
complete a hard copy of the questionnaire or participate using 
a Survey Monkey questionnaire online. The sample size was 
estimated based on previous experience with DCE studies,(21) 
which suggested that a sample size of 200–300 women and 
50–100 HPs was suffi cient to determine the main effects and 
identify signifi cant differences in preferences for test attributes 
between subgroups.
The questionnaire consisted of three sections: Section A – DCE 
choice sets; Section B – structured questions related to IPD and 
NIPT; and Section C – demographic questions (Appendix 1). 
The questionnaire was modifi ed from that used in a previous 
United Kingdom (UK) DCE study(21) that has been shown to 
generate plausible results. The attributes used in our DCE were 
the same as those used in the UK study, except for the attribute 
levels, which were updated in the present study to match the 
current clinical attributes of NIPT and invasive testing. The 
chosen attributes covered the major differences between NIPT 
and invasive testing, namely accuracy (levels of 95%, 99% 
and 100%), time of results (10 weeks, 12 weeks and 16 weeks of 
gestation), risk of miscarriage (small [1%] or none) and amount of 
information provided (trisomies 21, 18 and 13 only, or these three 
aneuploidies plus additional information on other chromosomal 
abnormalities). As detailed in the study by Hill et al,(23) the number 
of possible combinations of attributes and levels was reduced 
statistically from 32 scenarios (23 × 22) to nine. After an internal 
consistency check, an extra choice set with one obviously 
superior test was included, resulting in a total of ten pairwise 
choice sets. Each attribute occurred with equal frequency across 
the choice sets and there was no overlap in attribute levels within 
each choice set. Both the women and HPs were asked to select 
Test A, Test B or neither for their respective choice sets.
The structured questions relating to prenatal testing included 
a direct choice between NIPT and an invasive test. NIPT was 
described as a blood test that was 99% accurate, able to detect 
DS, Edwards syndrome and Patau syndrome, and having no risk 
of miscarriage. It was also explained that following a positive 
result, an invasive test with a small risk of miscarriage would be 
advised. The invasive test was described as 100% accurate, able 
to test for DS, Edwards syndrome or Patau syndrome, and able 
to provide additional information about rare genetic conditions 
that may cause other health problems. It was also stated that the 
test was invasive and had a 1% risk of miscarriage. The women 
were also asked whether they had ever undergone or would 
undergo prenatal testing for DS, their reasons for accepting or 
declining prenatal testing, and whether they had had a previous 
miscarriage. They were asked to rank six attributes in order of 
‘most important’ to ‘least important’. Demographic questions for 
the women included age, ethnicity, educational level and number 
of children, and those for HPs included job title, number of years 
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in practice, age and gender. The questionnaire took approximately 
20 minutes to complete.
A conditional logit regression model was used to analyse the 
DCE data for both the women and HPs.(26) Mean centred coding 
was used for the attributes, ‘accuracy’ and ‘time of results’, while 
effect coding was used for the attributes, ‘risk of miscarriage’ 
and ‘amount of information provided’. A constant term was 
included in the model to allow for the choice of neither test.(27) 
Coeffi cients generated by the regression analysis were given a 
‘+’ or ‘–’ sign to indicate the direction of the preference for each 
attribute. The signifi cance and size of the coeffi cients could 
be used to estimate the relative importance of the attributes. 
Willingness to accept a trade-off was measured using the ratio 
of two coeffi cients (marginal rates of substitution [MRS]). These 
MRS values allowed for the comparison of different attributes 
using a common scale.(24) Positive coeffi cients for the attributes, 
accuracy, amount of information provided and risk of miscarriage 
were anticipated, and participants were expected to prefer tests 
that provide higher accuracy, more information and greater safety. 
A negative coeffi cient for time of results was expected, indicating 
a preference for receiving earlier test results.
The preferences of the women and HPs were compared. 
Additional subgroup analyses for women were performed to 
examine differences between the women based on: type of 
healthcare (private vs. subsidised); age (< 35 vs. ≥ 35 years); 
religious faith; ethnicity; history of miscarriage (previous 
miscarriage vs. none); and personal experience with DS (knowing 
or having a child with DS vs. not knowing or having a child 
with DS). All analyses were carried out using Stata Statistical 
Software 12.0 (StataCorp LP, College Station, TX, USA). 
A p-value < 0.05 was considered statistically signifi cant.
RESULTS
Overall, 308 women were recruited from NUH. Of these, seven 
women were excluded from the study; two failed to correctly 
answer the internal consistency question and fi ve did not complete 
all the choice sets. The mean age of the 301 women included in 
the study was 30.7 ± 4.97 years. A total of 74 HPs were recruited, 
but fi ve were excluded – one due to an incorrect consistency 
question and four who did not complete the choice sets. The vast 
majority of HPs who responded were obstetricians/gynaecologists, 
as most of the patient counselling for prenatal testing in Singapore 
is delivered by obstetricians. The demographic data of the women 
and HPs is summarised in Tables I and II, respectively.
Among the 237 women who ranked the attributes, 98 (41.4%) 
rated safety as the most important, with accuracy as the second 
highest rated attribute. Almost half of the women (49.4%) 
ranked time of results as the least important aspect of the test, 
with cost being the second least important attribute (Fig. 1a and 
Appendix 2). In contrast, 64.1% of HPs rated accuracy as their 
most important consideration, with safety as the second most 
important (Fig. 1b and Appendix 2).
All four attributes examined using the DCEs (i.e. accuracy, 
time of results, risk of miscarriage and amount of information 
provided) were important to women in their decision-making 
process (Appendix 2, Table III). Positive conditional logit analysis 
regression coeffi cients for accuracy, full information and low 
miscarriage risk indicated that these attributes were preferred by 
both the women and HPs, while negative coeffi cients for time 
of results indicated that receiving results at an earlier gestational 
Table I. Demographics of the women.
Variable No. (%)
Healthcare type (n = 301)
Private 192 (63.8)
Subsidised 109 (36.2)
Age (yr) (n = 291)
< 35 224 (77.0)
≥ 35 67 (23.0)
Gestation period (wk)* 29.2 ± 7.37
Ethnicity (n = 284)
Chinese 105 (37.0)
Malay 55 (19.4)
Indian 52 (18.3)
Others 72 (25.4)
Highest qualiﬁ cation (n = 289)
No qualiﬁ cation 7 (2.4)
GCSE or GCE ‘O’ level 49 (17.0)
GCE ‘A’ level 25 (8.7)
University degree 117 (40.5)
Others 91 (31.5)
Religion (n = 267)
Christianity 54 (20.2)
Buddhism 31 (11.6)
Islam 71 (26.6)
Hinduism 29 (10.9)
Others 5 (1.9)
None 77 (28.8)
No. of children (n = 287)
None 166 (57.8)
1 68 (23.7)
≥ 2 53 (18.5)
Do you have a child with DS? (n = 256)
Yes 1 (0.4)
No 255 (99.6)
Do you know a child with DS? (n = 279)
Yes 54 (19.4)
No 225 (80.6)
Have you had/are you likely to have prenatal 
testing for DS? (n = 282)
Yes 230 (81.6)
No 52 (18.4)
No. of previous miscarriages (n = 289)
None 227 (78.5)
≥ 1 62 (21.5)
Subtotals may not add up to 301 due to missing responses and percentage values 
may not add up to 100% due to rounding up. *Data presented as mean ± standard 
deviation. DS: Down syndrome; GCE ‘A’ level: Singapore-Cambridge General 
Certiﬁ cate of Education Advanced Level; GCE ‘O’ level: Singapore-Cambridge 
General Certiﬁ cate of Education Ordinary Level; GCSE: General Certiﬁ cate of 
Secondary Education
Original  Art ic le
301
age was more desirable. These fi ndings had been previously 
reported(23) and meet a priori expectations, thereby supporting 
the validity of the results. The women prioritised low miscarriage 
risk, while the HPs had a stronger preference for accuracy and 
early results. MRS analysis showed that the women were willing 
to wait more than 2.5 times as long for the results and accept a 
4% reduction in accuracy as compared to HPs, in order to have 
a test without risk of miscarriage. Of the 40.9% of women who 
did not make a trade-off between their choices, 70.7% always 
chose the test without risk of miscarriage. Of the 29.0% of HPs 
who were unwilling to make a trade-off, 50.0% always chose the 
test with the highest accuracy (Appendix 2, Table IV).
The results of the subgroup analysis are summarised in 
Table III. Approximately two-thirds of the women (n = 192; 
63.8%) received private healthcare, with the remainder receiving 
subsidised care. There was no signifi cant difference in attribute 
preferences between these two subgroups. A comparison among 
ethnic groups showed that preference for safety was valued most 
by Chinese women. Older patients (aged ≥ 35 years) placed more 
emphasis on safety compared to younger women, and women 
who had a previous miscarriage also valued safety more than 
women who had not.
Overall, of the 282 women who responded to the question, 
“Have you had/are you likely to have prenatal testing for DS? ”, 
230 (81.6%) said that they would choose to undergo some form 
of prenatal testing, while 52 (18.4%) said that they would not 
(Table I). Among women who would choose to undergo prenatal 
testing, there was a signifi cantly higher preference for accuracy, 
whereas those who would not undergo prenatal testing had a 
signifi cantly higher preference for safety (Table IV).
When given a direct choice among IPD, NIPT or neither test, 
41.4% (n = 116) of the 280 women who responded opted for 
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Fig. 1 Bar charts show ranked preferences for six prenatal test attributes among (a) women and (b) health professionals, with test attributes ranked in 
order of preference from 1 (highest priority) to 6 (lowest priority).
1b
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Table II. Demographics of the health professionals.
Variable No. (%)
Age* (yr) 41.1 ± 11.9
Profession (n = 66)
Obstetrician/gynaecologist 41 (62.1)
Nurse 15 (22.7)
Others (e.g. midwife) 10 (15.2)
No. of years in profession (n = 62)
≤ 5 18 (29.0)
6–15 21 (33.9)
16–25 11 (17.7)
≥ 26 12 (19.4)
Gender (n = 66)
Male 21 (31.8)
Female 45 (68.2)
Subtotals may not add up to 69 due to missing responses. *Data presented as 
mean ± standard deviation. 
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IPD, 47.1% (n = 132) preferred NIPT and 11.4% (n = 32) said 
that they would not take either test (Table V). Analysis of the 
discrete choice sets for women who would choose either IPD, 
NIPT or neither test showed that women who would choose 
NIPT or neither test placed a greater emphasis on test safety than 
women who would choose IPD in the direct choice question. 
Women who would choose IPD in the direct choice question 
placed greater value on full information than those who would 
choose NIPT or neither test. Approximately equal numbers 
of women aged < 35 years would choose either NIPT or IPD 
(43.5% vs. 43.9%; Fig. 2 and Appendix 2, Table V). However, 
women aged ≥ 35 years were more likely to choose NIPT over 
IPD (62.3% vs. 29.5%, p = 0.0052). Women experiencing their 
fi rst pregnancy were equally likely to choose IPD or NIPT, as 
compared to those with one or more children. No signifi cant 
difference was seen between the proportion of women who would 
opt for NIPT and women who would opt for IPD among those 
with or without a religious faith. However, in the group with a 
religious faith, 16.5% indicated they would not take either test, 
whereas in the group without a religious faith, only 2.8% would 
not take either test. There was a signifi cantly higher proportion of 
Christians who would choose NIPT over IPD (62.3% vs. 17.0%, 
p = 0.0001), but no signifi cant differences were seen among the 
other religious faiths. Women who had a previous miscarriage 
or knew a child with DS were signifi cantly more likely to choose 
NIPT over IPD. Private patients were more inclined to choose 
NIPT (p = 0.0057), whereas subsidised patients would more 
likely choose IPD (p = 0.0265). Chinese women were more likely 
to choose NIPT over IPD, while Indian women preferred IPD; 
there was no difference among Malay women or those from the 
‘Others’ category.
When given a direct choice, 55.1% of HPs preferred to offer 
NIPT, 39.3% preferred IPD and 5.8% would not recommend 
either test. Obstetricians favoured NIPT over IPD (60.4% 
vs. 33.3%, p = 0.036; data not shown), while nurses and 
midwives preferred IPD over NIPT (64.7% vs. 29.4%, p = 0.038).
DISCUSSION
Overall, we found that when making decisions regarding prenatal 
testing, women in Singapore, like those in other countries,(21-23,28) 
place greater emphasis on test safety, while HPs place higher 
value on accuracy and early testing. We found that women 
who had a previous miscarriage, were aged ≥ 35 years or knew 
a child with DS gave higher priority to a test that does not 
carry a risk of miscarriage. Chinese women showed a greater 
Table III. Subgroup analysis of women’s preferences.
Parameter Accuracy p-value Time of 
results
p-value Comprehensive 
information
p-value No risk of 
miscarriage
p-value
Healthcare type
Private (n = 192) 0.177 0.0840 −0.084 0.2163 0.428 0.4502 1.285 0.3918
Subsidised (n = 109) 0.227 −0.058* 0.352 1.193
Ethnicity
Chinese (n = 105) 0.188 0.7191 −0.056† 0.1652 0.400 0.9560 1.471 0.0038
Indian (n = 52) 0.208 −0.103 0.442 1.192
Malay (n = 55) 0.235 −0.061† 0.477 0.955
Others (n = 72) 0.207 −0.109 0.417 1.386
Age (yr)
< 35 (n = 224) 0.197 0.700 −0.083 0.3668 0.431 0.8987 1.19 0.0003
≥ 35 (n = 67) 0.211 −0.060† 0.447 1.68
History of miscarriage
Yes (n = 62) 0.245 0.2211 −0.085 0.7521 0.340 0.4179 1.793 0.0001
No (n = 227) 0.196 −0.076 0.449 1.198
*p < 0.001 was statistically signiﬁ cant. †p < 0.05 was statistically signiﬁ cant; for all other coefﬁ cients, p < 0.0001.
Table IV. Results of conditional logit regression analysis comparing 
women who would and would not choose prenatal testing.
Attribute Coefﬁ cient p-value
Prenatal 
testing 
(n = 230)*
No prenatal 
testing 
(n = 52)†
Accuracy 0.218 0.133 0.0300
Time of results −0.083 −0.045‡ 0.2075
Full information 0.424 0.504 0.5878
No risk of 
miscarriage
1.281 1.732 0.0074
*No. of observations = 6,892; pseudo-R2 = 0.4001. †No. of observations = 1,527; 
pseudo-R2 = 0.1761. ‡p-value for coefﬁ cient was not signiﬁ cant. Coefﬁ cient 
p < 0.0001.
Table V. Results of conditional logit regression analysis comparing 
women who would choose NIPT, IPD or neither.
Attribute Coefﬁ cient* p-value
NIPT 
(n = 132)†
IPD
(n = 116)‡
Neither
(n = 32)§
Accuracy 0.187 0.236 0.167 0.2096
Time of results −0.079 −0.092 −0.078¶ 0.8425
Full information 0.302 0.592 0.342** 0.0257
No risk of miscarriage 1.683 0.866 2.296 < 0.0001
*p < 0.0001 for all coefﬁ cients. †No. of observations = 3,915; pseudo-R2 = 0.4858. 
‡No. of observations = 3,414; pseudo-R2 = 0.3289. §No. of observations = 1,107; 
pseudo-R2 = 0.2479. ¶p-value for coefﬁ cient was not signiﬁ cant. **p < 0.05 
was statistically signiﬁ cant for coefﬁ cient. IPD: invasive prenatal diagnosis; 
NIPT: noninvasive prenatal testing
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preference for test safety compared to the other ethnic groups 
examined. Given a direct choice between NIPT and IPD, previous 
miscarriage, age ≥ 35 years, knowing a child with DS, Christian 
faith and Chinese ethnicity were indicators for selection of NIPT. 
Interestingly, although women receiving both subsidised and 
private healthcare have demonstrated no signifi cant difference 
with regard to preferences for any of the test attributes, private 
patients would prefer to opt for NIPT, while subsidised patients 
would prefer IPD when given a direct choice.
Clear differences in preferences for test attributes between 
women and HPs highlight that when counselling women 
about NIPT, HPs should keep in mind that women’s views and 
preferences may differ from their own. In addition, to ensure 
that their women patients consider beyond test safety and to 
support informed decision-making, HPs should make an effort to 
discuss the various attributes of the prenatal test options available 
and highlight the limitations of these tests. HPs’ preference for 
accuracy over all other attributes for a new prenatal test may be 
indicative of a greater understanding about the limitations of NIPT, 
and the risk of both false-positive and false-negative results from 
NIPT. Good counselling is needed to ensure that autonomous 
informed consent is promoted.(29)
Three-quarters of the women in this study indicated that 
they would undergo some form of prenatal testing. Of those 
who responded, when given a choice between NIPT, IPD or 
neither test, 47.1% would choose NIPT, 41.4% would choose 
IPD and a sizable proportion (11.4%) would choose neither 
test. In comparison to many other countries,(23) both HPs and 
women in Singapore were more likely to choose an invasive test 
over NIPT when given a direct choice. The decision to opt for 
IPD over NIPT appears to be driven by a preference for having 
as much information as possible, since women who chose IPD 
were found to place greater value on having full information than 
women who chose NIPT or no test. There is evidence that women 
from some other countries also show a preference for IPD over 
NIPT,(23) or would prefer not to have any prenatal testing.(23,30,31) 
Therefore, while it is likely that many women will decide to 
have NIPT, it is important that HPs discuss alternatives to NIPT, 
such as invasive testing and the option of no testing at all, during 
pre-test counselling.
Both the women and HPs in our study emphasised 
comprehensive information from a prenatal test for decision-
making, and it appears that many would choose IPD over NIPT to 
maximise the information available to them. Recent developments 
in sequencing technology and algorithms have allowed for 
analysis of a number of additional conditions, including sex 
chromosome abnormalities,(32,33) microdeletions(34,35) and rare 
aneuploidies (such as trisomies 22 and 16).(36) However, the 
sensitivity of these tests is unknown, and they have not been 
validated in clinical practice, which will inevitably increase 
the false-positive rate. Thus, there continues to be a need for 
confirmatory invasive testing.(37) Furthermore, HPs need to 
consider the additional counselling that will be required, both 
pre- and post-test, if additional fi ndings are integrated into NIPT. 
At present, in Singapore, samples taken for IPD are karyotyped 
and this can detect major trisomies and other rearrangements 
that are microscopically visible. A chromosomal microarray is 
only performed if fetal sonographic anomalies raise suspicion of 
a microdeletion syndrome (e.g. cardiac anomalies in DiGeorge 
syndrome). Therefore, obstetricians in Singapore generally 
have to counsel only patients on trisomies 21, 18 and 13. In 
addition to the additional knowledge required for an expanded 
panel, there are time constraints for obstetricians and very few 
trained genetic counsellors in Singapore. A study in Hong Kong 
showed that patients were able to understand the limitations of 
NIPT, with more than 90% of patients appreciating the potential 
for false-negative and false-positive results, but being less 
knowledgeable on the more complicated aspects.(38) In order to 
provide stakeholders with the comprehensive knowledge they 
desire, a greater range of disorders will have to be added to the 
Fig. 2 Bar chart shows subgroup analysis for women giving a response to a direct choice between IPD (invasive prenatal diagnosis), NIPT (noninvasive 
prenatal testing) or neither test. DS: Down syndrome.
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NIPT panels. There have been concerns that this would result 
in women having to assimilate too much information prior to 
giving proper informed consent. However, there is also a high 
chance of detecting a maternal abnormality (e.g. the mother may 
be a carrier of a sex chromosome abnormality(39) or a DiGeorge 
mutation(40)). Some cases of maternal malignancy have even been 
detected by NIPT.(41,42) Depending on the platform used, which 
affects the likelihood of these additional fi ndings, some or all of 
these eventualities must be explained to the patient.
We have shown that even in a small country such as 
Singapore, there are signifi cant differences in women’s views on 
prenatal testing, indicating that individualised, parent-directed 
counselling is required. For example, older mothers and those 
who have had a previous miscarriage are particularly concerned 
about safety and, thus, may be more inclined to opt for NIPT. 
Chinese women tended to give the highest priority to the safety 
of the baby, as seen in both the discrete choice analysis of test 
attributes and their preference for NIPT over IPD, whereas Indian 
women preferred IPD over NIPT. In the present study, women 
of Chinese ethnicity were slightly older than the rest (31.4 years 
vs. 30.4 years, p = 0.044), and it is thus possible that older age 
could have contributed to their preference for NIPT. It is also 
probable that cultural factors played a part in these preferences. 
In order to make an informed choice, it is essential that women 
understand the tests that they are being offered. As demonstrated 
by Farrell et al,(17) Latina women in the United States with poorer 
English competency (and lower levels of education, in general) 
had a lower uptake of NIPT and also lacked understanding that 
NIPT does not test for all chromosomal abnormalities. Since 
Singapore is ethnically diverse, it would be important to consider 
the provision of patient information leafl ets in multiple languages. 
In addition, counselling should be provided by a multilingual HP, 
and if that is not the case, a translator should be present.
Although the women in the present study stated that the cost 
of the test was not a high priority, when faced with the reality 
of an expensive test, it is possible that there will be a limit to 
the price that they are willing to pay. NIPT is an expensive test, 
costing SGD 1,100–2,500. In Singapore, an invasive procedure 
costs approximately SGD 1,100 for private patients; therefore, 
there is not much difference in cost between NIPT and the slightly 
less expensive IPD. However, the cost of an invasive test can 
be covered using funds from the compulsory Medisave savings 
scheme that all Singaporeans must contribute to, whereas NIPT is 
an entirely out-of-pocket expense. As discussed earlier, although 
there was no difference in the preferences of subsidised and 
private patients for DS test attributes, when given the choice of 
an IPD or NIPT, the majority of subsidised patients would choose 
IPD while the majority of private patients would choose NIPT. 
There are many possible explanations for this, one of which is 
the perceived higher cost of NIPT, since it is a new technology. 
A study in Hong Kong showed that signifi cantly more women 
would opt for self-funded NIPT as a contingent second-line test, 
rather than a fi rst-line test, after a cFTS (freely available in public 
hospitals).(38) In Singapore, a cFTS costs SGD 270 for a private 
patient and SGD 130 for a subsidised patient. Thus, it is possible 
that the same outcome would be seen in Singapore if patients 
were given these options.
In our clinic, a contingent screening model is being 
implemented, whereby women with ‘low’ cFTS risk (> 1:1,000) 
are advised that no further screening is necessary. Those with 
intermediate or high risk (range 1:2–1:1,000) are counselled 
on the options of NIPT or IPD. Studies have shown that the 
introduction of NIPT decreased the likelihood of a patient 
declining further testing following a high-risk cFTS screen. 
A study by Chetty et al reported a decrease from 52.8% to 
21.2%,(43) while other studies have shown a signifi cant reduction 
in invasive testing subsequent to the availability of NIPT.(43-45) 
In light of our fi nding that there is an approximately equal 
preference for NIPT and IPD, it will be interesting to see how 
the widespread introduction of NIPT in Singapore will affect 
women’s interest in IPD. Additionally, it will be interesting to 
see whether women’s uptake of cFTS will change with more 
widespread use of NIPT.
There were several limitations to our study. Firstly, the study 
cohort was a convenience sample from the population who 
participated voluntarily. This may have resulted in bias toward 
those with strong views on prenatal testing and the results may 
thus not be generalisable to the entire population. For example, 
40.5% of women who took part were highly educated and 
hence, their views may not be representative of the Singapore 
population. Previous studies have also shown that interest 
in and uptake of NIPT is greater among women with higher 
levels of education.(17,46) Secondly, only 37.0% of women who 
participated were Chinese, and this does not match the overall 
Singapore population, which is 74.3% Chinese. In addition, 
a large proportion of the Chinese women who visited our 
clinic were originally from mainland China and did not have 
English as their fi rst language; since the questionnaire was set 
in English, participation would have been more challenging for 
these women. Thirdly, participants were recruited from only 
two centres, and thus, their preferences may not be refl ective of 
those of women in the whole country. Considerable variation 
in the uptake of DS screening has been demonstrated among 
different regions in the UK(47) and Netherlands;(48) although this 
is less likely to be an issue in Singapore, given its small size and 
the small number of maternity units (only nine) in the country, 
the demographics of the women attending these centres may 
nevertheless vary. Fourthly, although the HPs included in the 
study completed all the DCE choices, many did not answer 
all of the demographic data questions, and we were thus 
unable to conduct a detailed subgroup analysis for this group 
of participants. Finally, only four attributes of prenatal tests 
were evaluated. In reality, decisions about healthcare often 
involve multiple factors, with cost likely to play a key part in 
decision-making. Also, when faced with a real-life situation 
rather than a hypothetical one, women may opt for a different 
course. We did not, however, explore any of the reasons 
behind the participants’ preferences or investigate how they 
viewed the tests, although these would be interesting areas for 
future studies.
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In conclusion, we have found that, in general, women in 
Singapore who opt to undergo DS screening have a preference 
for safety, while HPs prioritise accuracy of results over other 
aspects. It is essential that HPs are aware of the differences in 
women’s preferences in order to provide non-biased counselling. 
In addition, HPs need to give patients adequate information on the 
full range of tests available, as well as spend time explaining the 
benefi ts and limitations of each option while showing sensitivity 
to the cultural differences among their patients.
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WOMEN’S VIEWS OF DIAGNOSTIC TESTS FOR DOWN SYNDROME DURING PREGNANCY
BACKGROUND
Diagnostic tests for Down syndrome can vary in a number of ways, including:
• Accuracy: Tests can vary in how accurate they are. The tests described here can identify 95%, 99% or 100% of babies with 
Down syndrome during pregnancy. (Please see the separate sheet for more information on accuracy.)
• Time in pregnancy when results are received: Tests vary in when they can be done and how long it takes to get a result. 
With the tests described here you could get your results at 10 weeks, 12 weeks or 16 weeks in pregnancy.
• Risk of miscarriage: Some tests have no risk of miscarriage. Others have a small risk (1% risk) of  miscarriage. A 1% risk 
means that one out of every 100 women who have a test will have a miscarriage.
• Information from tests: Generally, prenatal tests can give two types of information.
   Simple information: These tests will only tell you whether or not the baby has one of the three most common conditions 
caused by changes in the chromosomes – Down syndrome, Edwards syndrome or Patau syndrome.
   Comprehensive information: These tests will tell you whether or not the baby has one of the three most common 
conditions caused by changes in the chromosomes (including Down syndrome) and will also give information about 
whether some rare conditions are present, which may cause learning disability, developmental delay or other health 
problems.
  Tests that give comprehensive information look in detail at all of the baby’s chromosomes. Changes can include 
additional, missing or rearranged chromosome material. The effects of these changes can vary and severity will depend 
upon the parts of chromosomes that are involved. Some changes can result in severe disabilities, but these are very 
rare. Furthermore, in some cases, it may be diffi cult to predict what problems, if any, the child may have and others 
may only become signifi cant in adult life.
SECTION A: THE FOLLOWING QUESTIONS ASK WHAT FEATURES OF PRENATAL 
TESTS ARE MOST IMPORTANT TO YOU.
1. Please rank the following test features in order of importance to you.
(1: most important; 6: least important)
⁯ Test as early as possible.
⁯ Test with the greatest level of accuracy.
⁯ Test that has a low fi nancial cost for patients.
⁯ Test as safe as possible, with the lowest possible risk of a miscarriage.
⁯  Test that diagnoses Down syndrome and gives additional information about conditions that may cause learning disability, 
developmental delay or other health problems, even if there is a possibility of fi nding results of unknown signifi cance.
⁯ Test with the shortest waiting time for results.
2. Please read the following and answer the question according to your own views.
Candice is 10 weeks pregnant and when she has her fi rst antenatal appointment she is told about two different diagnostic tests 
for Down syndrome. The doctor tells her that she does not have to take either test if she does not want to. It is her choice.
Test 1: The test is 99% accurate and will tell you whether or not the baby has Down syndrome, Edwards syndrome or Patau 
syndrome. This test will not give any additional information about the health of the baby. The test is a blood test and there is 
no risk of miscarriage. However, if the result is positive, your doctor may recommend an invasive test, which has a 1% risk of 
miscarriage.
Test 2: The test is 100% accurate and will tell you whether or not the baby has Down syndrome, Edwards syndrome or Patau 
syndrome. This test will also give additional information about rare conditions that may cause learning disability, developmental 
delay or other health problems. This is an invasive test and there is a 1% risk of miscarriage.
Imagine you are Candice and tell us what you would choose to do.
⁯ I would have Test 1.
⁯ I would have Test 2.
⁯ I do not wish to have either test.
 APPENDIX 1
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SECTION B: THE FOLLOWING QUESTIONS REQUIRE YOU TO COMPARE BETWEEN 
TWO PRENATAL TESTS FOR DOWN SYNDROME AND INDICATE WHICH ONE YOU 
WOULD CHOOSE.
There are ten choices listed below. Each choice involves two different diagnostic tests that will tell you during pregnancy whether 
or not the baby has Down syndrome. The tests are hypothetical and are not available in any hospital.
Please consider each choice separately and tick the box to show which option you would prefer: A, B or neither.
Choice 1 Test A Test B
Accuracy 99% 100%
Time of results 10 weeks 12 weeks
Risk of miscarriage Small risk (1%) No risk 
Information from test Comprehensive 
information 
Simple information
Which test would you prefer? (Choose only one)
⁯ Test A ⁯ Test B ⁯ Neither
Choice 2 Test A Test B
Accuracy 100% 95%
Time of results 10 weeks 12 weeks
Risk of miscarriage No risk Small risk (1%)
Information from test Simple information Comprehensive 
information 
Which test would you prefer? (Choose only one)
⁯ Test A ⁯ Test B ⁯ Neither
Choice 3 Test A Test B
Accuracy 100% 95%
Time of results 16 weeks 10 weeks
Risk of miscarriage Small risk (1%) No risk
Information from test Simple information Comprehensive 
information 
Which test would you prefer? (Choose only one)
⁯ Test A ⁯ Test B ⁯ Neither
Choice 4 Test A Test B
Accuracy 95% 99%
Time of results 10 weeks 12 weeks
Risk of miscarriage No risk Small risk (1%)
Information from test Simple information Comprehensive 
information 
Which test would you prefer? (Choose only one)
⁯ Test A ⁯ Test B ⁯ Neither
Choice 5 Test A Test B
Accuracy 95% 100%
Time of results 16 weeks 10 weeks
Risk of miscarriage Small risk (1%) No risk 
Information from test Simple information Comprehensive 
information 
Which test would you prefer? (Choose only one)
⁯ Test A ⁯ Test B ⁯ Neither
Choice 6 Test A Test B
Accuracy 95% 99%
Time of results 12 weeks 16 weeks
Risk of miscarriage Small risk (1%) No risk 
Information from test Simple information Comprehensive 
information 
Which test would you prefer? (Choose only one)
⁯ Test A ⁯ Test B ⁯ Neither
Choice 7 Test A Test B
Accuracy 99% 100%
Time of results 12 weeks 16 weeks
Risk of miscarriage No risk Small risk (1%)
Information from test Simple information Comprehensive 
information 
Which test would you prefer? (Choose only one)
⁯ Test A ⁯ Test B ⁯ Neither
Choice 8 Test A Test B
Accuracy 100% 95%
Time of results 12 weeks 16 weeks
Risk of miscarriage No risk Small risk (1%)
Information from test Comprehensive 
information 
Simple information
Which test would you prefer? (Choose only one)
⁯ Test A ⁯ Test B ⁯ Neither
Choice 9 Test A Test B
Accuracy 99% 100%
Time of results 16 weeks 10 weeks
Risk of miscarriage No risk Small risk (1%)
Information from test Simple information Comprehensive 
information 
Which test would you prefer? (Choose only one)
⁯ Test A ⁯ Test B ⁯ Neither
Choice 10 Test A Test B
Accuracy 95% 99%
Time of results 16 weeks 10 weeks
Risk of miscarriage No risk Small risk (1%)
Information from test Comprehensive 
information 
Simple information
Which test would you prefer? (Choose only one)
⁯ Test A ⁯ Test B ⁯ Neither
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SECTION C: SOME QUESTIONS ABOUT YOU.
1. How old are you? ___________
2. What is your relationship status?
 ⁯ Single  ⁯ In a relationship
3. What is your highest educational qualifi cation? (Please choose one)
 ⁯ No qualifi cation
 ⁯ GCSE or GCE ‘O’ level
 ⁯ GCE ‘A’ level or similar
 ⁯ Higher education or similar
 ⁯ Other (please specify): ____________________
4. Do you have a religious faith?
 ⁯ Yes  ⁯ No
 If yes, please specify: __________________
5. Which of the following best describes you? (Please choose one)
 ⁯ Chinese  ⁯ Japanese  ⁯ Indian
 ⁯ Malay  ⁯ Caucasian ⁯ Pakistani
 ⁯ Black – African ⁯ Black – Other ⁯ Bangladeshi
 ⁯ Others
6. Do you have any children?
 ⁯ Yes, I have __ child(ren) ⁯ No
7. Are you currently pregnant?
 ⁯ Yes  ⁯ No
 If yes, how many weeks pregnant are you? ________
8. Have you had a previous miscarriage?
 ⁯ Yes  ⁯ No
9. I have had or am likely to have prenatal testing for Down syndrome during pregnancy.
 ⁯ Strongly agree  ⁯ Agree ⁯ Disagree  ⁯ Strongly disagree
  If you chose strongly agree or agree, please indicate which statement best matches why you have chosen to have a 
prenatal test.
 ⁯ So I can plan and prepare for the possibility of having a child with Down syndrome.
 ⁯ To help me make a decision around termination of pregnancy.
 ⁯ I would want as much information about the baby as possible.
 ⁯ Because my partner or family would want me to.
 ⁯ Because my doctor suggested it.
 ⁯ Because it is part of the routine prenatal care that women have in pregnancy.
 ⁯ Other (please specify) ________________________________
  If you chose strongly disagree or disagree, please indicate which statement best matches why you have chosen not to 
have a prenatal test.
 ⁯ I would never have a termination of pregnancy, so there is no point in having a test.
 ⁯ It would cause a lot of anxiety if I found out the baby had a health problem.
 ⁯ I would not want to know and then have to make a decision about what to do next.
 ⁯ Because my partner or family would not want me to have a test.
 ⁯ I would prefer not to know.
 ⁯ Other (please specify) ________________________________
10. Do you have a child with Down syndrome?
 ⁯ Yes ⁯ No
11. Does anyone you know have a child with Down syndrome?
 ⁯ Yes ⁯ No
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Table I. Ranked preferences for prenatal test attributes by women.
Attribute %
1 2 3 4 5 6
Early test 18.1 15.6 17.7 27.9 12.7 8.0
Accuracy 27.9 32.1 26.6 9.3 3.0 1.3
Cost 5.1 9.7 8.0 18.1 29.5 29.5
Safety 41.3 22.4 20.7 11.0 4.2 0.4
Full information 10.6 18.1 22.8 19.8 19.4 9.3
Time of results 1.3 4.6 4.2 10.6 30.0 49.4
Some women did not rank all six attributes. 1: most important; 6: least 
important
Table II. Ranked preferences for prenatal test attributes by health 
professionals.
Attribute %
1 2 3 4 5 6
Early test 6.3 15.6 20.3 21.9 15.6 20.3
Accuracy 64.1 25.0 6.3 3.1 1.6 0
Cost 6.3 4.7 18.8 18.8 28.1 23.4
Safety 18.8 46.9 20.3 9.4 4.7 0
Full information 4.7 6.3 28.1 23.4 7.8 29.7
Time of results 0 3.1 6.3 23.4 42.2 25.0
Five health professionals did not complete this section. 1: most important; 
6: least important.
Table III. Results of conditional logit regression analysis for women and HPs.
Attribute Women (n = 301) HPs (n = 69) p-value
Coefﬁ cient (95% CI)* p-value Coefﬁ cient (95% CI)† p-value
Accuracy 0.195 (0.167–0.222) < 0.0001 0.322 (0.259–0.386) < 0.0001 0.0003
Time of results −0.075 (−0.095 to −0.055) < 0.0001 −0.131 (−0.173 to −0.089) < 0.0001 0.0180
Full information 0.401 (0.305–0.496) < 0.0001 0.485 (0.278–0.691) < 0.0001 0.4696
No miscarriage risk 1.250 (1.149–1.350) < 0.0001 0.802 (0.582–1.023) < 0.0001 0.0003
*No. of observations = 8,982; pseudo-R2 = 0.2969. †No. of observations = 2,052; pseudo-R2 = 0.3876. CI: conﬁ dence interval; HPs: health professionals
Table IV. Women and health professionals (HPs) who did not make trade-offs with their choices.
Parameter No. (%)
Women (n = 301) HPs (n = 69)
Chose tests with the highest accuracy for all options 19 (6.3) 10 (14.5)
Chose tests with the earliest time for all options 1 (0.3) 1 (1.4)
Chose tests with full information for all options 5 (1.7) 3 (4.3)
Chose tests with no risk for all options 87 (28.9) 6 (8.7)
Chose neither for all options 11 (3.7) 0 (0)
Total 123 (40.9) 20 (29.0)
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Table V. Percentage of women, according to demographic categories, who would select NIPT, IPD or neither.
Parameter No. No. (%)
NIPT (n = 133) IPD (n = 117) Neither (n = 36)
Age (yr)
< 35 214 94 (43.9)* 93 (43.5) 27 (12.6)
≥ 35 61 38 (62.3) 18 (29.5) 5 (8.2)
Has religious faith
No 72 35 (48.6) 35 (48.6) 2 (2.8)
Yes 200 89 (44.5) 78 (39.0) 33 (16.5)
Declared faith
Buddhist 28 14 (50.0) 12 (42.9) 2 (7.1)
Christian 53 33 (62.3)* 9 (17.0) 11 (20.8)
Hindu 26 13 (50.0) 13 (50.0) 0 (0.0)
Muslim 55 21 (38.2) 29 (52.7) 5 (9.1)
Sikh 3 1 (33.3) 2 (66.7) 0 (0.0)
Taoist 3 2 (66.7) 1 (33.3) 0 (0.0)
Other 4 1 (25.0) 2 (50.0) 1 (25.0)
Already has children
No 158 74 (46.8) 63 (39.9) 21 (13.3)
Yes 121 53 (43.8) 53 (43.8) 15 (12.4)
Previous miscarriage
No 213 91 (42.7) 95 (44.6) 27 (12.7)
Yes 57 33 (57.9)* 15 (26.3) 9 (15.8)
Knows a child with DS
No 216 95 (44.0) 98 (45.4) 23 (10.6)
Yes 50 26 (52.0)† 12 (24.0) 12 (24.0)
Healthcare type
Private 183 97 (53.0)* 64 (35.0) 22 (12.0)
Subsidised 101 35 (34.7)† 52 (51.5) 14 (13.9)
Ethnicity
Chinese 100 61 (61.0)* 31 (31.0) 8 (8.0)
Indian 52 18 (34.6)† 30 (57.7) 4 (7.7)
Malay 48 20 (41.7) 20 (41.7) 8 (16.7)
Others 67 23 (34.3) 28 (41.8) 16 (23.9)
A binomial test was used to determine whether there was a signiﬁ cant difference between the number of women choosing IPD or NIPT in each category. 
*p < 0.001 was statistically signiﬁ cant. †p < 0.05 was statistically signiﬁ cant. DS: Down syndrome; IPD: invasive prenatal diagnosis; NIPT: noninvasive prenatal testing
